증식성 당뇨망막병증에서 발생한 신생혈관에 대한 베바시주맙의 치료효과

Therapeutic Effects of Intravitreal Bevacizumab Injection for Retinal Neovascularization Secondary to Proliferative Diabetic Retinopathy

Purpose: To evaluate the short-term effects of a single intravitreal injection of bevacizumab (Avastin) for the management of new vessels (NV) associated with proliferative diabetic retinopathy (PDR). Methods: A non-randomized study of 19 PDR patients (20 eyes) who had active NV was analyzed prospectively. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 4, and 8 after intravitreal injection of 1.25 mg of bevacizumab. The main outcome measures included changes in total area of fluorescein leakage from active NV and best corrected visual acuity (BCVA). Results: Twenty eyes of 19 patients (12 men [63.2%], 7 women [36.8%]) were included and all patients completed the 8-week study follow-up period. The mean age of participants was 47.05±12.48 years. At baseline, NV area was 23.02±21.80 mm2. The area of active NV decreased significantly to 4.96±9.18 mm2, 1.11±4.96 mm2 and 4.55±5.11 mm2 (p<0.05) at 1, 4 and 8 weeks after injection, respectively. At week 4, no leakage was observed in 19 eyes. The mean logMAR BCVA improved from 0.59±0.49 at baseline to 0.56±0.47, 0.55±0.73 and 0.51±0.50 at weeks 1, 4, and 8, respectively. No significant adverse events were observed. Conclusions: Short-term results suggest that intravitreal injection of bevacizumab is associated with a rapid regression of retinal neovascularization secondary to PDR.